COMPANY
Our Story
The promise of gene editing is immense. So is the challenge of making it safe. We built Broken String to close that gap.
Off-target effects: the hardest question in gene editing
Gene editing has the potential to transform medicine. Technologies like CRISPR allow scientists to precisely modify DNA, opening the door to treatments for diseases that were once thought untreatable. But the promise of gene editing also comes with an important challenge: understanding exactly what happens in the genome when edits are made.
For researchers developing gene editing therapies, one of the hardest questions to answer is where else an edit might occur beyond the intended target. Detecting these off-target effects is critical for ensuring the safety of new treatments, yet historically the tools available to scientists have been slow, fragmented, and difficult to interpret.
Born from pioneering research
Our technology originates from research at Cardiff University, with AstraZeneca as industrial sponsor, developing a powerful new way to detect DNA break events across the genome.
INDUCE-seq® enables researchers to see where genome editing tools create double-strand breaks, at the intended target and anywhere else in the genome.
Today, we work with gene editing companies around the world to help them understand editing outcomes earlier and more completely, supporting safer development and faster progress toward clinical therapies.
Our goal is simple: to bring clarity to gene editing development, helping scientists turn the promise of gene editing into safe and effective treatments for patients.
Making off-target analysis faster, clearer and actionable
Wet-lab assay
A robust assay that captures genome-wide DNA break events with exceptional sensitivity using INDUCE-seq®.
Bioinformatics platform
Complex sequencing data transformed into clear, ranked insights that researchers can act on with confidence.
Earlier answers
Supporting safer development and faster progress toward clinical therapies for gene editing companies worldwide.
Broken String Biosciences, today announced the submission of a Master File (MAF) to the U.S. Food and Drug Administration (FDA) for its INDUCE-seq® platform, marking a significant step in supporting regulatory adoption of genome-wide DNA break analysis in gene editing programs.
Alongside rebranding, we have redesigned our website so researchers can easily access a comprehensive resource library and gain a clear understanding of how our INDUCE-seq platform can be applied across gene editing workflows to maximize value in development pipelines.
To drive the company’s commercial expansion, Terry Pizzie has been appointed as CEO, bringing extensive experience from leading and scaling global life science businesses.